Novel mechanisms of G-protein-coupled receptors functions: AT1 angiotensin receptor acts as a signaling hub and focal point of receptor cross-talk

• Published in: Baillière's best practice & research. Clinical endocrinology & metabolism Vol. 32; no. 2; pp. 69 - 82
• Main Authors: Tóth, András D., Turu, Gábor, Hunyady, László, Balla, András
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.04.2018
• Subjects: angiotensin II; bias; dimerization; GPCR; receptor cross-talk; RAS; dimerization; AT1R; EGFR; α2CAR; angiotensin II; bias; GPCR; receptor cross-talk; VSMC; AngII; β2AR; HB–EGF
• ISSN: 1521-690X; 1878-1594
• DOI: 10.1016/j.beem.2018.02.003

AT1 angiotensin receptor (AT1R), a prototypical G protein-coupled receptor (GPCR), is the main receptor, which mediates the effects of the renin-angiotensin system (RAS). AT1R plays a crucial role in the regulation of blood pressure and salt-water homeostasis, and in the development of pathological conditions, such as hypertension, heart failure, cardiovascular remodeling, renal fibrosis, inflammation, and metabolic disorders. Stimulation of AT1R leads to pleiotropic signal transduction pathways generating arrays of complex cellular responses. Growing amount of evidence shows that AT1R is a versatile GPCR, which has multiple unique faces with distinct conformations and signaling properties providing new opportunities for functionally selective pharmacological targeting of the receptor. Biased ligands of AT1R have been developed to selectively activate the β-arrestin pathway, which may have therapeutic benefits compared to the conventional angiotensin converting enzyme inhibitors and angiotensin receptor blockers. In this review, we provide a summary about the most recent findings and novel aspects of the AT1R function, signaling, regulation, dimerization or oligomerization and its cross-talk with other receptors, including epidermal growth factor (EGF) receptor, adrenergic receptors and CB1 cannabinoid receptor. Better understanding of the mechanisms and structural aspects of AT1R activation and cross-talk can lead to the development of novel type of drugs for the treatment of cardiovascular and other diseases.